Skip to main content
Clinical Trials/JPRN-UMIN000004749
JPRN-UMIN000004749
Recruiting
N/A

A study to evaluate the long-term effect of pulmonary hypertension on prognosis, activities of daily living (ADL), cardiac function and pulmonary function in patients with COPD and IPF, respectively, according to baseline severity of pulmonary hypertension and the efficacy and safety of the Tracleer (bosentan hydrate) tablet for prognosis, activities of daily living, cardiac function and pulmonary function in patients with COPD and IIPs, respectively, according to baseline severity of pulmonary hypertension.

Department of Respiratory Medicine, Chiba-Hokusoh Hospital, Nippon Medical School0 sites160 target enrollmentDecember 18, 2010

Overview

Phase
N/A
Intervention
Not specified
Conditions
Patients with COPD or IPF (WHO functional class II, III or IV), without hypoxia (PaO2 at rest&lt
Sponsor
Department of Respiratory Medicine, Chiba-Hokusoh Hospital, Nippon Medical School
Enrollment
160
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
December 18, 2010
End Date
September 30, 2022
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Department of Respiratory Medicine, Chiba-Hokusoh Hospital, Nippon Medical School

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • 1\) Patients already on bosentan or other drugs for pulmonary hypertension 2\) Patients with any disease that can cause right heart overload 3\) Patients with hypoxemia (PaO2\<60mmHg at rest or after 6 minutes walk). 4\) Women who are pregnant or who may be pregnant, and lactating women 5\) Patients with moderate or severe liver disorder 6\) Patients under treatment with ciclosporin, tacrolimus, or glibenclamide 7\) Other patients judged by the investigator to be inappropriate as a subject of this study

Outcomes

Primary Outcomes

Not specified

Similar Trials